Redwood City, United States
Arcellx, founded in 2015, is a clinical-stage biotechnology company headquartered in the United States. Specializing in biopharma, biotechnology, health care, life sciences, and pharmaceuticals, the company has made significant strides in the realm of cell therapy.
As of its last major development, Arcellx became part of Kite, a division under Gilead Sciences. Kite is renowned as a global biopharmaceutical enterprise which actively pursues solutions for achieving cures through advanced cell therapies.
The notable milestone in Arcellx's journey was a $7.80B acquisition by Gilead Sciences, finalized on 01 February 2026. This substantial investment underscores the strategic value and potential the company represents within the broader biopharmaceutical landscape.
Overall, Arcellx offers a compelling opportunity within the industry, benefiting from its avant-garde approach to cell therapy as well as the backing and resources of a robust parent organization, Kite.
NexImmune, Inc.
